Pharmaceutical, Biotech, and Healthcare Industry News
Recent legislative changes are having a profound impact on the pharmaceutical industry, influencing everything from drug pricing and development to market access and patient care. Understanding these changes is crucial for industry stakeholders to navigate the evolving landscape effectively. Key Legislative Areas Affecting Pharma Impact...
Real-World Data (RWD) is revolutionizing the pharmaceutical industry, offering unprecedented insights into drug efficacy, safety, and patient outcomes outside the controlled environment of clinical trials. This wealth of information is transforming how drugs are developed, approved, and monitored post-market. Understanding Real-World Data in Pharmaceuticals Real-World...
The Food and Drug Administration withdrew its emergency use authorizations the two antiviral drugs promoted by President Trump, despite concerns surrounding their effectiveness and safety.
The FDA has approved the very first treatment for COVID-19, and the drugmaker has donated their “entire supply.”
The drug President Trump has often touted as a treatment for COVID-19, despite it being, as yet, unproven, is set to begin a Phase III clinical trial.
Executives from some of the world’s largest pharmaceutical and biotechnology companies met with President Trump to discuss the timeline of a coronavirus vaccine.
A report from the FDA’s Drug Shortages Task Force has found that there is no one single cause for drug shortages, nor an easy solution to stop them.
The EpiPen drug maker has reached a settlement over a lawsuit with the Securities and Exchange Commission.
Headlines proclaimed a potential game changer in treating cardiovascular disease—Vascepa—and company shares quickly soared, but the study behind the claim remains a mystery.
